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Type IV secretion (T4S) systems translocate DNA and protein
effectors through the double membrane of Gram-negative bacte-
ria. The paradigmatic T4S system in Agrobacterium tumefaciens is
assembled from 11 VirB subunits and VirD4. Two subunits, VirB9
and VirB7, form an important stabilizing complex in the outer
membrane. We describe here the NMR structure of a complex
between the C-terminal domain of the VirB9 homolog TraO
(TraOCT), bound to VirB7-like TraN from plasmid pKM101. TraOCT
forms a -sandwich around which TraN winds. Structure-based
mutations in VirB7 and VirB9 of A. tumefaciens show that the
heterodimer interface is conserved. Opposite this interface, the
TraO structure shows a protruding three-stranded -appendage,
and here, we supply evidence that the corresponding region of
VirB9 of A. tumefaciens inserts in the membrane and protrudes
extracellularly. This complex structure elucidates the molecular
basis for the interaction between two essential components of a
T4S system.
TraO–TraN  structural biology  bacterial conjugation  pilus 
DNA transfer
Type IV secretion (T4S) systems mediate the translocation ofDNA and protein substrates across bacterial cell envelopes
(1, 2). One T4S system subfamily, the conjugation machines,
transmit DNA substrates to bacterial recipients and are respon-
sible for widespread dissemination of antibiotic resistance and
other virulence traits among bacterial pathogens (3). A second
T4S subfamily, the effector translocators, deliver DNA or pro-
tein substrates to eukaryotic target cells to aid in establishment
of infection (4).
In Gram-negative bacteria, the T4S systems are composed of
a translocation channel spanning the inner and outer membranes
and an extracellular pilus (3, 5–7). The translocation channel
elaborated by the phytopathogen Agrobacterium tumefaciens is
composed of an inner membrane translocase whose subunits
include the VirD4, VirB4, and VirB11 ATPases, the polytopic
subunit VirB6, and bitopic subunits VirB8 and VirB10. In the
periplasm, the channel likely is composed of VirB2 pilin and the
periplasmic domains of VirB8 and VirB9. At the outer mem-
brane (OM), a pore must form for passage of the substrate and
the pilus, but, at this time, the composition or structure of this
pore is not known. Extending from the cell surface is the pilus
composed of VirB2 pilin and minor components VirB5 and
VirB7. VirB7, a lipoprotein, interacts with VirB9 (see below) but
also can be identified in the extracellular milieu even indepen-
dently of other VirB protein production (1).
For the A. tumefaciens VirB/D4 machine and related T4S
systems, the VirB9 subunit is the best candidate for assembling
as an OM channel or pore (6–9). VirB9-like proteins share weak
sequence similarities with pore-forming secretins associated with
the types II and III secretion systems, which also export mac-
romolecular substrates across the OMs of Gram-negative bac-
teria (10). As shown for many secretins, VirB9 fractionates with
the OM as a complex with a cognate lipoprotein, in this case
VirB7 (11). VirB7 interacts with and stabilizes VirB9, and
formation of the VirB7–VirB9 heterodimer, in turn, stabilizes
other type IV components (12). In the A. tumefaciens VirB/D4
T4S system, a disulfide bridge is formed between the reactive
Cys-24 and Cys-262 residues of VirB7 and VirB9, respectively
(12–15). VirB9 proteins and secretins also form higher-order
multimers, with themselves or with other T4S proteins, detect-
able by chemical cross-linking (15–17). However, secretins typ-
ically are refractory to detergent solubilization from the OM and
display a heat-modifiable mobility shift in SDS-polyacrylamide
gels, as is also the case for OM -barrel proteins, including porins
and other small molecule transporters (18). VirB9 proteins
instead migrate as monomers and do not show heat-modifiable
mobility in protein gels (8). These differences may reflect a more
dynamic or reversible self-association of VirB9 or suggest that
VirB9-like proteins adopt a different architecture at the OM
than the ring-shaped secretins.
In this study, we solved the NMR structure of a complex
formed between the pKM101-encoded TraOC-terminal domain
(TraOCT) and full-length TraN, homologs, respectively, of VirB9
and VirB7. TraOCT adopts a -sandwich fold, around which
TraN winds. This structure defines the molecular basis of VirB9
interaction with VirB7. In a mutational analysis of the A.
tumefaciens VirB7 and VirB9 subunits, we supply corroborative
experimental support for the heterodimer interface identified by
the TraN–TraOCT NMR structure. Interestingly, two edge
strands of the TraOCT -sandwich (4 and 6) together with the
5 strand, located opposite the TraN-binding site, form an
appendage that protrudes markedly from the -sandwich, and
the equivalent loop in VirB9 is partially exposed on the A.
tumefaciens bacterial surface.
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Structure Description. We identified a soluble fragment (residues
177–294; TraOCT) of TraO, the VirB9 homolog encoded by the
pKM101 conjugation system, and purified it with a soluble
version (residues 17–49) of TraN, the VirB7 homolog encoded
by the same system. Details of how such fragments were iden-
tified, the complex produced, and the structure determined by
NMR are provided in supporting information (SI) Figs. 6 and 7
and SI Table 1.
TraOCT has an immunoglobin-like -sandwich fold consisting
of nine -strands and a short stretch of 310 helix between the first
and second strands (Fig. 1). By using DALI (19) to compare
TraOCT to known structures, the structure is most similar to the
recently described Near Transporter domain of IsdH/HarA from
Staphylococcus aureus (DALI Z-score 5.6) and the human
interleukin 4 receptor (DALI Z-score 5.5). Immunoglobin-like
folds are found in many proteins of diverse function, and thus the
structural similarity does not yield any functional insight. Six
strands (1–3, 7–9) form the body of the sandwich; three
(4–6) are more loosely connected and form a distinctive
-appendage protruding out of the body of the sandwich. The
first sheet comprises strands 5, 4, 8, 9, and 1; the second
sheet comprises 2, 3, 7, and 6 (Fig. 1). Because the residue
numbering for the two proteins does not overlap, it should be
clear that, in the following analysis, residue numbers 21–42 refer
to TraN, and residue numbers 177–271 refer to TraOCT (Fig. 2).
Overall, TraN forms an extended structure that wraps around 1
of TraOCT and caps one of the two edges of the -sandwich. In
addition, TraN interacts with 9, 2, and N-terminal residues of
the 1–2 linker. The interface buries 1,680 Å2 of surface area.
From N to C terminus along the TraN sequence, the first major
contact with TraOCT is between carbon atoms of Pro-23, Glu-24,
and Pro-25 (TraN) andMet-192 of the 1–2 linker and Val-261,
Gly-263 of 9 (TraO) (Fig. 3A). Asp-26 amide is H-bonded by
Gln-189 in the 1-2 linker. Trp-27 packs onto a shelf compris-
ing Gly-263 and Arg-265 of 9 and Val 185 of 1 (Fig. 3A).
Fig. 1. Overview of TraOCT/TraN complex structure. (A) Schematic topology
diagram of TraOCT with -strands color-ramped as in SI Fig. 7C. The 310 helix is
colored white. TraN is represented as a yellow line crossing strands 1, 2, and
9 of TraOCT. Residues Trp-27 and Val-33, two major contact points with
TraOCT, are shown. Strands 4 and 6 are shown at an angle to their adjacent
strands to reflect their weaker H-bonding interactions. (B) Rotation of the
model through 180° about the vertical axis with respect to C to show strands
4, 5, and 6 on the opposite face to the TraN-binding site. Residues N214
and 224 (N216 and N226 in A. tumefaciens) VirB9 are shown in ball-and-stick
representation. (C) Stereo diagram of structure showing TraOCT in cartoon
representation with loops, 310 helix, and -strands colored as in A. TraN is
shown as a stick model with carbon atoms colored yellow, nitrogen atoms
colored blue, and oxygen atoms colored red. The same representations and
color scheme is used in B and C. PyMOL was used for all structure figures
(www.pymol.org).
Fig. 2. Sequence conservation of the VirB9–VirB7 interaction site. (A) Se-
quence alignment of VirB9 homologs: pKM101 TraO (pKM101, NP511196);A.
tumefaciens VirB9 (A. tume, NP396496); B. suis VirB9 (B. suis, NP699268);
pSB102 TraK (pSB102, NP361041); Bordetella pertussis VirB9 (B. pert,
NP882293); Actinobacillus actinomycetemcomitans magB09 (A. acti,
NP067575); pR388 TrwF (pR388, CAA57030); Bartonella henselae TrwF (B.
hens, CAF28337). Identical residues are shaded red, and conserved residues are
shaded pink. The portion of the sequence modeled as structure is shown as a
dashed line above the sequence, gray boxes containing colored arrows show
the-strands, and the 310 helix is shown as a black box. (B) Sequence alignment
of VirB7 homologs: pKM101 TraN (pKM101, NP511194);A. tumefaciensVirB7
(A. tume, NP536291); B. suis VirB7 (B. suis, AAN33275); pSB102 TraI (pSB102,
NP361043); Bordetella pertussis VirB7 (B.pert, NP882291); Actinobacillus
actinomycetemcomitans magB07 (A. acti, NP067577); pR388 TrwH (pR388,
FAA00034); B. henselae TrwH (B. hens, AAM82208). VirB7 homologs were
manually aligned based on the lipid-modified cysteine (green), the position of
the A. tumefaciens cysteine, and the conserved ‘‘P[ILV]NK’’ VirB9-interaction
motif (cyan). The portion of the sequence modeled as structure is shown as a
dashed line above the alignment. InA and B, the cysteine residues involved in
A. tumefaciensVirB9–VirB7 disulfide bond formation are colored orange, and
key residues mutated in the A. tumefaciens proteins are shown in bold and
underlined.
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Ser-28, Asn-29, and Thr-30 form a sharp turn in the TraN chain
that positions the main-chain NH and O of Val-31 to H-bond
with the O and NH of Met-186 in 1 (Fig. 3B). Pro-32 prevents
this -sheet-like H-bond pattern from developing down the
TraN chain and positions Val-33 to insert into a hydrophobic
pocket between the two sheets of the -sandwich. This striking
hydrophobic contact contributes to the TraOCT hydrophobic
core as the deeply buried side chain of Val-33 inserts between
Tyr-184, Met-186 of 1, and Val-200 of 2 (Fig. 3 B and C).
Finally, the 1H,15N HSQC (Heteronuclear Single Quantum
Correlation) spectrum of 15N TraN/unlabeled TraOCT clearly
shows that the N protons of Asn-34 are involved in a hydrogen
bond with TraOCT, because it has an unusual chemical shift of
N118 ppm and H 8.5 and 9.1 ppm and has a weaker intensity
signal than the other Asn/Gln side-chain TraN amides, suggest-
ing that it tumbles as part of the whole complex rather than
exhibiting internal f lexibility on a fast timescale (Fig. 2). Un-
fortunately, there is no information to indicate which TraOCT
atoms form H bonds with Asn-34.
The differences in the average chemical shifts (avg) between
the 1H-15N HSQC spectra of 15N-labeled TraOCT alone or in a 1:1
molar ratio with unlabeled TraN were mapped onto the structure
Fig. 3. Structural detail of the TraOCT–TraN interaction site. (A) Detail of the interaction between TraN residues 23–27 and TraOCT. TraOCT main chain is depicted
as a cartoon colored according to the scheme in Fig. 1. TraN and interacting side chains of TraOCT are shown as sticks colored white or yellow for carbon atoms
in TraOCT or TraN, respectively, blue for nitrogen, red for oxygen, and orange for sulfur. (B) Detail of the interaction between TraN residues 31–34 and TraOCT
using the same representation as A. (C) Surface representation of TraOCT colored white for no/low conservation, magenta for high conservation, and red for
identical residues as defined by Fig. 2A. Identical residues on the surface of TraOCT and V33 of TraN are labeled. (D) Surface representation of modeled A.
tumefaciens VirB9CT with the backbone ribbon of TraN superposed, shown in the same orientation as the pKM101 structure in C. VirB9CT is colored white for
carbon, blue for nitrogen, red for oxygen, and orange for sulfur. Potential locations of VirB7 cysteine residue 24 are marked with orange spheres, and the ‘‘PLN’’
sequence predicted to bind to the hydrophobic pocket is marked as cyan backbone.









of the TraOCT/TraN complex. All of the major differences lie very
close to the interface of the two proteins, which is consistent with
no global conformational changes in TraOCT upon TraN binding
(Fig. 4 A and B). We also examined the 1H-15N HSQC spectra of
15N-labeled TraOCT fractions that eluted from the gel filtration
column as a higher-molecular-weight species.When comparedwith
monomeric TraOCT, one extensive surface patch exhibited either
large differences in chemical shifts or ablation of cross-peak inten-
sity. This region covered strands 2, 3, 7, residues Lys-180,
Gln-183, and Tyr-184 in and around 1, and the 6–7 linker, and
overlaps partially with the TraN-binding site (Fig. 4B). This partial
overlap may explain how TraN prevents TraOCT oligomerization.
Conservation of the VirB7–VirB9 Interaction. Close homologs of
TraO were identified by using the Basic Local Alignment Search
Tool (BLAST) and were aligned by using ClustalW. The TraO/
VirB9 homologs are phylogenetically conserved, and the se-
quence alignment of pKM101 TraO and A. tumefaciens VirB9
C-terminal domains shows many identical or well-conserved
residues. We used the sequence alignment as the basis for
modeling the A. tumefaciens VirB9CT domain using Modeller
(20) and default settings (Fig. 3D). In A. tumefaciens, the
interacting VirB7/VirB9 proteins form a disulfide bridge be-
tween Cys-24 of VirB7 and Cys-262 of VirB9. These residues are
highlighted in the sequence alignments and on the modeled
structure (orange, Figs. 2 and 3D), showing that Cys-262 of A.
tumefaciens VirB9 is equivalent to Gly-263 of TraO. TraO
Gly-263 is very close to Pro-25 and Trp-27 of TraN, and it is
conceivable that the Cys-24 of A. tumefaciens VirB7 could be in
an equivalent position to either of those TraN residues.
It was not possible to identify all of the corresponding
TraN/VirB7 homologs by using BLAST or to align them by using
ClustalW because the sequences are short and divergent. How-
ever, one strikingly conserved feature of the TraN/VirB7 ho-
mologs is a P[ILV]NK motif that in TraN (residues 32–35)
interacts with a deep hydrophobic pocket on TraOCT (Figs. 2B
and 3C). This motif is located 15–17 residues from the lipidated
cysteine residue, a distance that might be crucial in defining the
position of VirB9 with respect to the membrane.
Mutational Analysis of the VirB7-VirB9CT Interface of A. tumefaciens.
We introduced mutations at residues predicted to form the
interface in the VirB7–VirB9 heterodimer of A. tumefaciens and
assayed for effects on dimerization, protein stability, and viru-
lence of the corresponding A. tumefaciens strains. In VirB7, we
mutated residues I28, F29, L31, and N32 in and around the
conserved ‘‘P[ILV]NK’’ motif (Fig. 2B) to alanine (SI Table 2).
Strains producing the two double mutants I28A/F29A and
L31A/N32A as well as the triple mutant I28A/F29A/N32D (L31
of A. tumefaciens is equivalent to V33 of TraN; Fig. 2) accumu-
lated the VirB7 derivatives at WT levels, but VirB9 was unde-
tectable, consistent with a predicted heterodimerization defect
(12). Strains producing the VirB7 mutant proteins accumulated
low levels of VirB10. These strains also were defective for
assembly of the disulfide bridge between Cys-24 residues of two
VirB7 monomers. As expected, strains producing the VirB7
mutant proteins failed to assemble T pili, transfer oncogenic
T-DNA to plants, and transfer a mobilizable IncQ plasmid to
recipient A. tumefaciens cells.
In VirB9, we introduced mutations in and around the hydro-
phobic pocket into which L31 (V33 in TraN) inserts (SI Table 2).
The VirB9 F203W (equivalent to residue W201 in TraOCT) and
A191M (equivalent to residueM186 in TraOCT) mutant proteins
could not be detected, consistent with a predicted heterodimer-
ization defect, although we cannot rule out the possibility of
other destabilizing effects, e.g., misfolding. These mutant pro-
teins also did not support pilus production, virulence, or gene
transfer. The V202W (equivalent to V200 in TraOCT) mutant
protein was stable and formed the VirB7 disulfide cross-link but
showed defects in functional assays. This mutation might still
perturb the dimer interface or formation of higher-order VirB7–
VirB9 multimers. Another mutation, L198F in the 1–2 linker,
also resulted in loss of detectable VirB9, pilus production, and
DNA transfer. Although we cannot exclude the possibility that
some of the mutations may result in protein instability, taken
together, engineered mutants in A. tumefaciensVirB7 and VirB9
appear to indicate that noncovalent interactions between VirB7
and VirB9 (notably between the P[ILV]NK motif of VirB7 and
the hydrophobic pocket of VirB9) are necessary to promote not
only the formation of the disulfide bridge between the proteins
but also to generate an active complex.
Evidence for Surface Accessibility of VirB9.One of the most intrigu-
ing features of the NMR structure of TraOCT and the modeled
structure of VirB9CT is the 4–6 region extending from the
C-terminal globular domain. We tested whether this region
spans the OM. Previously, we showed that dipeptide LG inser-
tions at several positions along the length of VirB9, including
insertions after N216 and N226, were permissive for VirB9
function (8). N216 is in the 3–4 loop, and the TraO equivalent,
N214, is on the surface of the protein at the furthest point of the
loop; N226 (N224 in A. tumefaciens VirB9) is located at the end
of 4 (Figs. 1B and 2). We thus introduced a FLAG epitope after
Fig. 4. Conformational changes in VirB9 upon binding of TraN. TraOCT shows
no global conformational change upon TraN binding. Differences in the
average chemical shift 1H-15N HSQC (avg) are plotted as a color ramp on the
surface of TraOCT. Blue surface represents residues that exhibit avg
0.1ppm, and red denotesavg0.9ppm or ablation of cross peak intensity.
(A) Difference between 15N-labeled TraOCT monomer alone and bound to
unlabeled TraN, shown from the same view as Fig. 1C. (B) Difference between
15N-labeled TraOCT monomer and dimer shown from same view as in A. TraN
is shown to indicate the partial overlap of residues at the TraN interface with
those exhibiting a high avg.
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N216 and N226 as well as Cys substitution mutations at N216,
N226, P227, and D228 to test for surface accessibility.
We initially observed that anti-VirB9 polyclonal antibodies
reacted with native VirB9 produced in WT cells by immunoflu-
orescence microscopy (SI Fig. 8). Most fluorescent foci were
located at A. tumefaciens cell poles, although foci also were
evident at other sites on the cell periphery, consistent with
previous findings (21, 22). These antibodies did not react with
intact cells of a virB9 mutant strain, establishing the specificity
of the reaction for VirB9.
Next, we assayed for surface accessibility of the FLAG
epitopes. As shown in Fig. 5A, the anti-FLAG antibodies reacted
with VirB9FL epitope-tagged at residue N226 but not with
material on the surfaces of intact cells producing native VirB9 or
cells producing the VirB9FL variant epitope-tagged at residue
N216. Most cells had polar foci, although foci were evident
elsewhere at the cell periphery similar to findings for native
VirB9 (21, 22). Upon conversion of cells to spheroplasts, both
VirB9FL variants reacted with the FLAG antibodies (Fig. 5A).
Fluorescence was more uniform than observed with whole cells,
possibly because of redistribution of the VirB9 variants upon
spheroplasting.
We also tested for surface accessibility of VirB9 by introducing
Cys residues at positions N216, N226, P227, and D228 and then
assaying for alkylation of these residues. The sulfhydryl reactive
reagent 3-(N-maleimidylpropionyl) biocytin (MPB) readily
crosses the OM, whereas 4-acetamido-4-maleimidylstilbene-
2,2-disulfonic acid (AMS) only inefficiently crosses the OM
because its molecular mass of 536 Da exceeds the exclusion limit
for porins. Thus, pretreatment of intact cells with AMS thus
should block surface-displayed Cys residues from MPB labeling
(23). As shown in Fig. 5B, most or all of native VirB9, which
dimerizes via its unique C262 residue with VirB7, reacted only
weakly with MPB, and labeling was unaffected by AMS pre-
treatment. The N216C mutant protein reacted with MPB, but
labeling was unaffected by AMS pretreatment, adding to evi-
dence that this residue resides in the periplasm. In contrast, MPB
strongly labeled the N226C substitution mutant in the absence of
AMS pretreatment, and labeling was significantly diminished in
AMS-pretreated cells. MPB also labeled the P227C and D228C
mutant proteins, albeit less strongly than N226C, and again AMS
pretreatment diminished MBP labeling. Similarly, native VirB9
and the N216C mutant protein did not react with mPEG-
maleimide, whose large size (5 kDa) restricts labeling exclusively
to surface-accessible Cys residues (Fig. 5B). By contrast, mPEG-
maleimide reacted with the N226C and P227C mutant proteins
and more weakly with the D228C mutant protein, as shown by
a mobility shift of 5 kDa. As observed with MPB labeling,
mPEG-maleimide labeled the N226C mutant protein most
strongly and the P227C and D228C mutant proteins progres-
sively more weakly. All of VirB9FL variants and Cys-substitution
mutants under study were fully functional insofar as the corre-
sponding strains translocated T-DNA and the IncQ plasmid
RSF1010 at WT frequencies and elaborated T pili (data not
shown). Taken together, therefore, results of the immunofluo-
rescence microscopy and scanning cysteine accessibility method
studies, supplied strong evidence that residues N226 and P227 of
native VirB9 are surface-displayed, indicating that the protrud-
ing 4–6 region identified in the NMR structure spans the A.
tumefaciens OM.
Conclusion
The structure of the VirB7-interacting domain of VirB9 bound
to VirB7 elucidates the molecular basis of the interaction
between the two proteins. The domain itself is an independent
folding unit, suggesting that full-length VirB9 is a modular
protein. The interface between the TraN and TraOCT is exten-
sive and unusual. Many interactions involving -fold-containing
proteins are mediated through -strand addition (termed -ad-
dition), whereby a -strand of one interacting partner is added
to the edge of a -sheet in the other interacting partner (24, 25).
TraN instead wraps around its binding partner perpendicularly
to the direction of the sandwich and wedges one of its residues
(V33) in the gap between the two -sheets. VirB9 exhibits a
defined structural scaffold, and sequence homology within the
VirB9 family of proteins is high, and, thus, the surface position
of interacting residues is likely to be similar across the VirB9
family of proteins. This may not be the case for the VirB7 family
of proteins, where sequence homology is low and no defined
structure was observed. However, the structure-based functional
studies presented here indicate that the VirB9/VirB7 interface is
conserved.
The T4S apparatus is a macromolecular machine that actively
assists protein or nucleoprotein secretion through the double
membrane of Gram-negative bacteria. This process should re-
quire passage through a pore at the OM, but identification of the
pore has not yet been possible. One possible candidate is the
VirB9 protein that is known to fractionate from the OM and is
strongly associated with VirB7, a small lipoprotein, which is
found only at the OM (8, 26). Here, we supply experimental
evidence that VirB9 is surface-exposed, and we identify a
minimal structure in the C-terminal domain, the 4–6 region,
involved in the OM topology. Our findings support a general
model that VirB9 is a component of an OM channel complex;
however, further studies are needed to determine the VirB9
stoichiometry, subunit composition, and overall structure of this
proposed channel.
T4S systems contribute to infectious diseases through the
exchange of genetic material, including antibiotic-resistance
Fig. 5. Surface accessibility of VirB9 Cys substitution mutations and FLAG
epitope tagged VirB9 derivatives. (A) Intact cells (Upper) and spheroplasts
(Lower) were reacted with anti-FLAG antibodies and examined by immuno-
fluorescence microscopy. Strains: B9, PC1009 with pBLC373 producing native
VirB9; 216 & 226, PC1009 producing VirB9FL derivatives with FLAG epitope at
these residues. (B) (Upper) Intact cells were incubated with the Cys reactive
reagent MPB with () or without (-) preblocking with AMS. (Lower) Intact cells
were untreated (-) or treated () with mPEG-maleimide (mPEG) (5 kDa).
Strains: B9, PC1009; B9(B9), PC1009(pBLC373) producing native VirB9;
PC1009 with pBLC373 derivatives carrying Cys substitutions at positions indi-
cated.









genes, among bacterial pathogens, and by the direct secretion of
macromolecules into eukaryotic cells. VirB7 and VirB9 form a
keystone interaction essential for assembly of the apparatus into
a functioning secretion system. The structure of the VirB7–
VirB9 interaction we present here provides the basis for a
rational approach to the disruption of this interaction in other
bacterial systems. Small molecules targeted against this interac-
tion may be useful drugs to combat human infectious diseases
where T4S plays a crucial role.
Materials and Methods
Protein Preparation, NMR Spectroscopy, and Structure Calculations.
Details of protein preparation, NMR spectroscopy, and struc-
tural calculations can be found in SI Text.
A. tumefaciens Strains and Plasmids, Protein Analyses and Immuno-
detection, Virulence, and Conjugation Assays.Details of this section
can be found in SI Text.
Immunofluorescence Microscopy. A. tumefaciens cells were prein-
duced for 4 h for synthesis of VirB proteins in broth induction
medium and then placed on a sterile microscope slide coverslip
and induced for an additional 24 h. Cells were fixed by
sequential additions of 0.1% polylysine (60 l) and 16%
paraformaldehyde–0.5% glutaraldehyde (100 l). After fixa-
tion, cells were treated with 100 mM TrisHCl, pH 7.4 (100 l),
with or without lysozyme (2 mg/ml) and EDTA (100 M).
Cells were incubated overnight with primary antibody (1:100
in PBS 1% BSA) specific for the FLAG epitope (M2) or VirB9
and then with the second antibody, Rhodamine red-X goat
anti-mouse IgG/M (for detection of the FLAG epitope) or
Alexa Fluor 488 goat anti-rabbit antibodies (for detection of
VirB9). Labeled cells were visualized in a BX60 microscope
(Olympus, Melville, NY) equipped with a magnification 100
oil immersion phase-contrast objective by either f luorescence
or differential interference contrast microscopy.
Labeling with MPB. Cysteine-accessibility experiments were car-
ried out as described (27, 28). Briefly, 2 OD600 of a induced A.
tumefaciens strain PC1009 producing Cys-substituted VirB9
derivatives were resuspended in 500 l of buffer A [100 mM
Hepes (pH 7.5)/250 mM sucrose/25 mM MgCl2/0.1 mM KCl).
Cells were untreated or treated with AMS (Molecular Probes,
Eugene, OR) (100 M final concentration) for 7 min at room
temperature, then treated with MPB (Molecular Probes) (100
M final concentration) for 5 min at 25°C. Biotinylation was
quenched with 20 mM -mercaptoethanol.
Labeling with Monomethoxy Polyethylene Glycol (mPEG)-Maleimide.
vir-induced cultures of A. tumefaciens strain PC1009 producing
Cys-substituted VirB9 derivatives were concentrated to an
OD600  20, washed, and resuspended in 500 l of 50 mM
NaHPO4 buffer, pH 7.0. Cells were untreated or treated with
AMS (100 M final concentration) for 7 min at room temper-
ature, washed to remove the AMS, and suspended in 500 l of
50 mM NaHPO4 buffer, pH 7.0. mPEG-maleimide (5-kDa
molecular mass; Nektar Therapeutics, San Carlos, CA) (5 mM
final concentration) was added, and cells were incubated for 5
min at 25°C. 2-Mercaptoethanol (20 mM final concentration)
was added to quench the reaction. Cells were incubated in
protein sample buffer at 65°C for 15 min, and mPEG-maleimide
modification of VirB9 variants was assessed by SDS/PAGE and
Western immunoblot analysis with anti-VirB9 antibodies.
Immunoprecipitation and Detection of Labeled Cys Residues. MPB-
labeled cells were solubilized, and VirB9 variants were immu-
noprecipitated to recover VirB9 from extracts containing other
MPB-labeled proteins as described (7). After SDS/PAGE and
protein transfer, nitrocellulose membranes were incubated in the
presence of avidin HRP (1:10,000 dilution of 2 mg/ml stock
solution; Pierce, Rockford, IL). Biotinylated proteins were de-
tected by chemiluminescence (Amersham Pharmacia, Piscat-
away, NJ).
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